Disease · HP_0001300

Parkinsonism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Parkinsonism. Diseases, record HP_0001300. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001300

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Parkinsonism
Open Targets ID: HP_0001300
Highest stage of its drugs: Approval, for 3 of its 18 drugs, from DailyMed and PMDA

Source Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMANTADINE HYDROCHLORIDE	CHEMBL1569	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
APOMORPHINE HYDROCHLORIDE	CHEMBL3187985	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
COBALAMIN	CHEMBL4297272	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
PYRIDOXINE	CHEMBL1364	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
APOMORPHINE	CHEMBL53	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARVEDILOL	CHEMBL723	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets32

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D2-like dopamine receptor	3	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	3	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	3	D2-like dopamine receptor agonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2/3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRB1	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor beta antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor beta antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor beta antagonist	Phase 2	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 32

See all 32 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02789020	Image Parkinson's Disease Progression Study	Phase 2	96	2023-09-06	Parkinson's Disease	RASAGILINE	Its record names the disease	ClinicalTrials.gov
NCT02265484	To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism	Not applicable	50		Cirrhosis Related Parkinsonism	BROMOCRIPTINE	Its record names the disease	ClinicalTrials.gov
NCT03790345	Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics	Phase 2/3	45		Schizophrenia, Drug Induced Movement Disorder, Unspecified, Oxidative Stress	COBALAMIN, PYRIDOXINE	Its record names the disease	ClinicalTrials.gov
NCT04218968	Cardiac Changes in Early Parkinson's Disease: A Follow up Study	Phase 2	15		REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease	CARVEDILOL	Its record names the disease	ClinicalTrials.gov
NCT00472355	Low Dose Apomorphine and Parkinsonism	Phase 2	0		Parkinson's Disease	APOMORPHINE	Its record names the disease	ClinicalTrials.gov
NCT03446807	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Phase 2	0		Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy	DROXIDOPA	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rasagiline vs Placebo: deaths from any cause	0 of 45	0 of 45	90	NCT02789020	Trial comparisons
Rasagiline vs Placebo: serious adverse events	0 of 45	0 of 45	90	NCT02789020	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30554466	DERIVED	1	PubMed
18268187	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001300

GET https://conductscience.org/api/diseases/v1/HP_0001300/targets?page=2

API reference For AI assistants